natgillin/translations-raw huggingface dataset:
Stressinkontinens er en medicinsk tilstand, hvor patienten oplever ufrivillig urinlækager under fysisk anstrengelse eller aktiviteter såsom latter, hoste, nysen, løft eller motion. 
Stress urinary incontinence is a medical condition in which patients have accidental loss or leakage of urine during physical exertion or activities such as laughing, coughing, sneezing, lifting, or exercise.
Lysfølsomhedsreaktioner 
Photo-sensitivity reactions
4.2 for information om patienter med let til moderat nyreinsufficiens. 
See section 4.2 for information on patients with mild or moderate renal dysfunction.
Hvis det vurderes, at der skal iværksættes en farmakologisk antidepressiv behandling, anbefales det at seponere behandlingen med YENTREVE gradvist (se pkt. 
If a decision to initiate antidepressant pharmacological therapy is taken, the gradual discontinuation of YENTREVE is recommended (see section 4.2).
Inden for hver enkelt frekvensgruppe er bivirkningerne opført opstillet efter, hvor alvorlige de er. 
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Antacida og H2-antagonister: Samtidig administration af YENTREVE med aluminium- og magnesiumholdige antacida eller med famotidin har ingen signifikant virkning på absorptionshastigheden eller absorptionsfraktionen af duloxetin efter en oral dosis på 40 mg. 
Antacids and H2 antagonists: Co-administration of YENTREVE with aluminium- and magnesiumcontaining antacids or with famotidine had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose.
Supra-ventrikulær arytmi, hovedsagelig atrieflimren6 
Supra-ventricular arrhythmia, mainly atrial fibrillation6
De hyppigst rapporterede bivirkninger hos patienter i behandling med YENTREVE i kliniske studier med SUI og andre lidelser i de nedre urinveje var kvalme, mundtørhed, træthed og forstoppelse. 
The most commonly reported adverse events in patients treated with YENTREVE in clinical trials in SUI and other lower urinary tract disorders were nausea, dry mouth fatigue and constipation.
Tilfælde af leverskade herunder alvorlig forhøjede leverenzymer (>10 gange den normale øvre grænse), hepatitis og gulsot er rapporteret for duloxetin (se pkt. 
Cases of liver injury, including severe elevations of liver enzymes (>10 times upper limit of normal), hepatitis and jaundice have been reported with duloxetine (see section 4.8).
YENTREVE er indiceret til behandling af kvinder med moderat til svær stressinkontinens (SUI). 
YENTREVE is indicated for women for the treatment of moderate to severe Stress Urinary Incontinence (SUI).
Spørg Deres læge eller apoteket til råds. 
You should ask your doctor or pharmacist for advice.
I følgende situationer kan De muligvis ikke bruge YENTREVE. 
The following are reasons why YENTREVE may not be suitable for you.
Duloxetin metaboliseres i udstrakt grad af oxiderende enzymer (CYP1A2 og det polymorfe CYP2D6) efterfulgt af konjugation. 
Duloxetine is extensively metabolised by oxidative enzymes (CYP1A2 and the polymorphic CYP2D6), followed by conjugation.
Samtidig brug af YENTREVE med selektive, reversible MAO-hæmmere som moclobemid, kan ikke anbefales (se pkt. 
The concomitant use of YENTREVE with selective, reversible MAOIs, like moclobemide, is not recommended (see section 4.4).
I kliniske studier er der observeret utilsigtede hændelser ved pludselig afbrydelse af behandlingen hos ca. 44% og 24% af patienterne behandlet med hhv. YENTREVE og placebo. 
In a clinical trial, adverse events seen on abrupt treatment discontinuation occurred in approximately 44% of patients treated with YENTREVE and 24% of patients taking placebo.
Forhøjede leverenzymer (ALAT, ASAT, basisk fosfatase) Akut leverskade 
Elevated liver enzymes (ALT, AST, alkaline phosphatase) Acute liver injury
• tænderskæren eller sammenbidte tænder, desorientering, manglende motivation, problemer med at opnå orgasme, mærkelige drømme 
• grinding or clenching the teeth, feeling disorientated, lack of motivation, difficulty or failure to experience orgasm, unusual dreams
Hver YENTREVE kapsel indeholder pellets af duloxetinhydrochlorid med en belægning, som beskytter dem mod mavesyre. 
Each capsule of YENTREVE contains pellets of duloxetine hydrochloride with a covering to protect them from stomach acid.
Kombinationsbehandling (duloxetin + bækkenbundsøvelser) viste større forbedring både med hensyn til brug af bind og tilstandsspecifikke livskvalitetsmålinger end YENTREVE alene eller bækkenbundsøvelser alene. 
Combined therapy (duloxetine + PFMT) showed greater improvement in both pad use and condition-specific quality of life measures than YENTREVE alone or PFMT alone.
Mani6 
Mania6
Tinnitus1 Ørepine 
Tinnitus1 Ear pain
• Fortæl Deres læge, hvis De ammer. 
• Tell your doctor if you are breast-feeding.
• brystsmerter, kuldefølelse, tørst, varmefølelse 
• chest pain, feeling cold, thirst, feeling hot
• besvær med at påbegynde vandladning, smertefuld vandladning, behov for vandladning i løbet af natten, hyppig vandladning, unormal urinlugt 
• difficulty to start urinating, painful urination, needing to pass urine during the night, frequent urination, abnormal urine odour
Se afsnit 4. 
3 See section 4.4.
Hunrotter, som fik duloxetin før og under parring samt i den tidlige drægtighedsperiode, havde nedsat fødeindtagelse og kropsvægt, afbrydelse af brunstcyklussen, et nedsat indeks for levendefødsler og overlevelse af afkom samt forsinket vækst hos afkommet ved udsættelse for systemisk påvirkning estimeret til at være højst ved den maksimale kliniske eksponering (AUC). 
Female rats receiving duloxetine before and during mating and early pregnancy had a decrease in maternal food consumption and body weight, oestrous cycle disruption, decreased live birth indices and progeny survival, and progeny growth retardation at systemic exposure levels estimated to be at the most at maximum clinical exposure (AUC).
Ved ophør af behandling med YENTREVE skal dosis gradvis reduceres over en periode på mindst en til to uger for at mindske risikoen for seponeringssymptomer (se pkt. 
When stopping treatment with YENTREVE the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8).
• frisk rødt blod i afføringen, inflammation i tyktarmen (kan medføre diarré) 
• passing bright red blood in your stools, inflammation of the large intestine (leading to diarrhoea)
CNS-lægemidler: Det anbefales at udvise forsigtighed, når YENTREVE tages sammen med andre centralt virkende lægemidler eller stoffer, herunder alkohol og sederende lægemidler (benzodiazepiner, morphinlignende præparater, antipsykotika, phenobarbital, sederende antihistaminer). 
CNS medicinal products: Caution is advised when YENTREVE is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products (e.g. benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).
På baggrund af duloxetins halveringstid skal der gå mindst 5 dage efter endt behandling med YENTREVE, før en behandling med en MAO-hæmmer påbegyndes (se pkt. 
Based on the half-life of duloxetine, at least 5 days should be allowed after stopping YENTREVE before starting an MAOI (see section
Almene symptomer og reaktioner på administrationsstedet Træthed 
General disorders and administration site conditions Fatigue
Både CYP2D6 og CYP1A2 katalyserer dannelsen af to hovedmetabolitter: glukuronidkonjugat af 4-hydroxy-duloxetin og sulfatkonjugat af 5-hydroxy-6-methoxy-duloxetin. 
Both cytochromes P450-2D6 and 1A2 catalyse the formation of the two major metabolites glucuronide conjugate of 4-hydroxy duloxetine and sulfate conjugate of 5-hydroxy 6-methoxy duloxetine.
Medicin der kan virke sløvende: Disse inkluderer medicin ordineret af Deres læge, herunder benzodiazepiner, stærk smertestillende medicin, antipsykotika, phenobarbital og sløvende antihistaminer. 
Medicines that cause sleepiness: These include medicines prescribed by your doctor including benzodiazepines, strong painkillers, antipsychotics, phenobarbital and sedative antihistamines.
Palpitationer Takykardi 
Palpitations Tachycardia
YENTREVE og bækkenbundsøvelser: I løbet af et blindt, randomiseret, kontrolleret 12-ugers studie viste YENTREVE større reduktioner i IEF i forhold til enten placebobehandlingen eller med bækkenbundsøvelser alene. 
YENTREVE and Pelvic Floor Muscle Training (PFMT): During a 12-week blinded, randomised, controlled study, YENTREVE demonstrated greater reductions in IEF compared with either placebo treatment or with PFMT alone.
Kontaktdermatitis Koldsved Øget tendens til at få blå mærker 
Dermatitis contact Cold sweat Increased tendency to bruise
Erfaringer fra undersøgelser har vist, at der er øget risiko for selvmordsadfærd hos unge under 25 år med psykiske forstyrrelser, som bliver behandlet med antidepressiv medicin. 
Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant
YENTREVE bør derfor ikke gives i kombination med potente CYP1A2-hæmmere som fluvoxamin (se pkt. 
Therefore YENTREVE should not be administered in combination with potent inhibitors of CYP1A2 like fluvoxamine (see section 4.3).
Eftersom sikkerheden af duloxetin hos spædbørn ikke er kendt, frarådes behandling med YENTREVE i ammeperioden. 
As the safety of duloxetine in infants is not known, the use of YENTREVE while breast-feeding is not recommended.
Andre lægemidlers virkning på duloxetin 
Effects of other medicinal products on duloxetine
YENTREVE må ikke anvendes sammen med CYP1A2 hæmmere, som fluvoxamin, ciprofloxacin og enoxacin, idet kombinationen resulterer i forhøjet plasmakoncentration af duloxetin (se pkt. 
YENTREVE should not be used in combination with CYP1A2 inhibitors, like fluvoxamine, ciprofloxacin or enoxacin since the combination results in elevated plasma concentrations of duloxetine (see section 4.5).
En lignende mekanisme hos kvinder, baseret på begrænset beviser fra urodynamiske og elektrofysiologiske studier, menes at medføre kraftigere uretral lukning under urinopbevaring med fysisk stress der kan forklare effekten af duloxetin i behandling af kvinder med stressinkontinens. 
A similar mechanism in women is believed to result in stronger urethral closure during urine storage with physical stress that could explain the efficacy of duloxetine in the treatment of women with SUI.
Hud og subkutane væv Øget perspiration 
Skin and subcutaneous tissue disorders Sweating increased
Monoaminoxidasehæmmere (MAO-hæmmere): De må ikke tage YENTREVE, hvis De tager, eller inden for de sidste 14 dage har taget et antidepressivt lægemiddel kaldet en MAO-hæmmer. 
Monoamine oxidase inhibitors (MAOIs): You should not take YENTREVE if you are taking or have recently taken (within the last 14 days) an antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Laktationen påvirkede ikke farmakokinetikken for duloxetin. 
Lactation did not influence duloxetine pharmacokinetics.
Der har dog også været tilfælde med duloxetin alene i doser på omkring 1000 mg. Tegn og symptomer på overdosering (duloxetin alene eller sammen med andre lægemidler) omfatter: Søvnighed, coma, serotoninsyndrom, kramper, opkastning og takykardi. 
Some fatalities have occurred, primarily with mixed overdoses, but also with duloxetine alone at a dose of approximately 1000 mg. Signs and symptoms of overdose (duloxetine alone or in combination with other medicinal products) included somnolence, coma, serotonin syndrome, seizures, vomiting and tachycardia.
CYP1A2-hæmmere: Da CYP1A2 er involveret i metaboliseringen af duloxetin, vil samtidig behandling med YENTREVE og potente CYP1A2-hæmmere sandsynligvis medføre højere koncentrationer af duloxetin. 
Inhibitors of CYP1A2: Because CYP1A2 is involved in duloxetine metabolism, concomitant use of YENTREVE with potent inhibitors of CYP1A2 is likely to result in higher concentrations of duloxetine.
28 hårde enterokapsler 56 hårde enterokapsler 98 hårde enterokapsler 140 hårde enterokapsler 
28 hard gastro-resistant capsules 56 hard gastro-resistant capsules 98 hard gastro-resistant capsules 140 hard gastro-resistant capsules
Det anbefales at udvise forsigtighed hos patienter i behandling med antikoagulantika og/eller lægemidler (f.eks. NSAID eller acetylsalisylsyre), som påvirker trombocytfunktionen, og hos patienter med kendt blødningstendens. 
Caution is advised in patients taking anticoagulants and/or medicinal products known to affect platelet function (e.g. NSAIDs or acetylsalicylic acid (ASA)), and in patients with known bleeding tendencies.
• søvnbesvær, ophidselse, mindre lyst til sex, angst, problemer med at falde i søvn 
• trouble sleeping, feeling agitated, less sex drive, anxiety, difficulty sleeping
Der er rapporteret om tilfælde af mydriasis i forbindelse med duloxetin, og der skal derfor udvises forsigtighed ved udskrivning af duloxetin til patienter med forhøjet intraokulært tryk eller til patienter med risiko for akut snævervinklet glaukom. 
Mydriasis has been reported in association with duloxetine, therefore, caution should be used when prescribing duloxetine in patients with increased intraocular pressure, or those at risk of acute narrowangle glaucoma.
For patienter med ukontrolleret hypertension, er der kontraindikation for opstart af behandling med YENTREVE, da det kan udsætte patienterne for en potentiel risiko for hypertensive kriser (se pkt. 
The initiation of treatment with YENTREVE is contraindicated in patients with uncontrolled hypertension that could expose patients to a potential risk of hypertensive crisis (see sections 4.4 and
YENTREVE er et lægemiddel til oral indtagelse til behandling af stressinkontinens (SUI) hos kvinder. 
YENTREVE is a medicine to be taken by mouth to treat Stress Urinary Incontinence (SUI) in women.
Spørg på apoteket, hvordan De skal bortskaffe medicinrester. 
Ask your pharmacist how to throw away of medicines you no longer use.
Hyppigheden af inkontinensepisoder: I alle fire studier havde den duloxetinbehandlede gruppe en gennemsnitlig reduktion i Incontinece Episode Frequence (IEF) på 50% eller mere sammenlignet med 
Incontinence Episode Frequency: In all four studies the duloxetine-treated group had a 50% or greater median decrease in IEF compared with 33% in the placebo-treated group.
S.A. Tel: + 34-91 623 17 32 
Spaly Bioquímica, S.A. Tel: + 34-91 623 17 32
Aggression og vrede4,6 
Hallucinations Aggression and anger4,6
Diarré Opkastning Abdominalsmerter Dyspepsi 
Diarrhoea Abdominal pain Vomiting Dyspepsia
Hvis De får usædvanlige symptomer, når De tager et af disse lægemidler sammen med YENTREVE, skal De kontakte Deres læge. 
These medicines increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with YENTREVE, you should see your doctor.
Steady-state koncentrationerne i modermælk er ca. en fjerdedel af plasmakoncentrationerne. 
Duloxetine is detected in breast milk, and steady-state concentrations in breast milk are about one-fourth those in plasma.
Effekten af 40 mg duloxetin to gange dagligt ved behandling af SUI blev vurderet i fire dobbeltblinde, placebokontrollerede studier, hvor der indgik 1913 kvinder (i alderen 22-83 år) med SUI. 
The efficacy of duloxetine 40 mg given twice daily in the treatment of SUI was established in four double-blind, placebo-controlled studies that randomised 1913 women (22 to 83 years) with SUI; of these, 958 patients were randomised to duloxetine and 955 to placebo.
YENTREVE er en hård enterokapsel. 
YENTREVE is a hard gastro-resistant capsule.
Bivirkninger kan blive mere almindelige ved samtidig brug af YENTREVE og naturlægemidler med indhold af perikon (Hypericum perforatum). 
Adverse reactions may be more common during concomitant use of YENTREVE and herbal preparations containing St John's wort (Hypericum perforatum).
Hududslæt Nattesved Urticaria 
Night sweats Urticaria
Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: +358 (0)9 8545 250 
Oy Eli Lilly Finland Ab Puh/Tel: +358-(0) 9 85 45 250
YENTREVE må ikke anvendes sammen med ikke-selektive, irreversible monoaminoxidasehæmmere - MAO-hæmmere (se pkt. 
YENTREVE should not be used in combination with nonselective, irreversible monoamine oxidase inhibitors - MAOIs (see section 4.5).
Elimination: Halveringstiden for duloxetin efter en oral dosis ligger på 8-17 timer (gns. 
Elimination: The elimination half-life of duloxetine ranges from 8 to 17 hours (mean of 12 hours).
• nervøsitet, koncentrationsbesvær, ændret smagsoplevelse, dårlig søvnkvalitet 
• feeling nervous, difficulty concentrating, changes in sense of taste, poor sleep quality
Urinretention6 Polyuri Nedsat urinmængde 
Urinary retention6 Polyuria
Hyponatriæmi, herunder tilfælde med serum-natriumværdier under 110 mmol/l, er blevet rapporteret efter indgivelse af YENTREVE. 
Hyponatraemia has been reported when administering YENTREVE, including cases with serum sodium lower than 110 mmol/l.
Blødningsabnormaliteter såsom ekkymoser, purpura og gastrointestinal blødning er set ved brug af selektive serotoningenoptagshæmmere - (SSRI-præparater) og serotonin/noradrenalingenoptagshæmmere (SNRI-præparater), herunder duloxetin. 
There have been reports of bleeding abnormalities, such as ecchymoses, purpura and gastrointestinal haemorrhage with selective serotonin reuptake inhibitors (SSRIs) and serotonin/noradrenaline reuptake inhibitors (SNRIs), including duloxetine.
YENTREVE 40 mg er tilgængelig i pakninger med 28, 56 og 98 og 140 hårde enterokapsler og i en multipakning med 196 (2 pakninger a 98) hårde enterokapsler. 
YENTREVE 40 mg is available in packs of 28, 56, 98 and 140 hard gastro-resistant capsules and in a multipack containing 196 (2 packs of 98) hard gastro-resistant capsules.
Må ikke opbevares ved temperaturer over 30°C. 
Do not store above 30° C.
EU/1/04/280/002 (28 hårde enterokapsler) EU/1/04/280/003 (56 hårde enterokapsler) EU/1/04/280/004 (98 hårde enterokapsler) EU/1/04/280/005 (140 hårde enterokapsler) 
EU/1/04/280/002(28 hard gastro-resistant capsules) EU/1/04/280/003 (56 hard gastro-resistant capsules) EU/1/04/280/004 (98 hard gastro-resistant capsules) EU/1/04/280/005 (140 hard gastro-resistant capsules)
Ved at kombinere YENTREVE med bækkenbundstræning kan der muligvis opnås en bedre effekt end ved hver af de to behandlinger alene. 
Combining YENTREVE with a pelvic floor muscle training (PFMT) programme may be more effective than either treatment alone.
(monoaminoxidasehæmmer) (se ”Brug af anden medicin sammen med YENTREVE”) 
- are taking other medicines containing duloxetine (see ‘Other medicines and YENTREVE')
I et embryotoxicitetstudie foretaget på kaniner blev der observeret en højere incidens af kardiovaskulæreog knogledeformationer, hvor hunkaninerne blev udsat for systemiske påvirkninger under den maksimale kliniske eksponering (AUC). 
In an embryotoxicity study in the rabbit, a higher incidence of cardiovascular and skeletal malformations was observed at systemic exposure levels below the maximum clinical exposure (AUC).
YENTREVE 40 mg findes i pakninger med 28, 56, 98, 140 og 196 (2 x 98) kapsler. 
YENTREVE 40 mg is available in packs of 28, 56, 98, 140 and 196 (2 x 98) capsules.
• (kløende) udslæt, natlig sveden, nældefeber, koldsved, øget tendens til blå mærker 
• (itchy) rash, night sweats, hives, cold sweats, increased tendency to bruise
I denne periode var der stigninger i HbA1C både i duloxetin- og standardbehandlingsgrupperne, men den gennemsnitlige stigning var 0,3% større i gruppen behandlet med duloxetin. 
In the extension phase of these studies, which lasted up to 52 weeks, there was an increase in HbA1c in both the duloxetine and routine care groups, but the mean increase was 0.3% greater in the duloxetinetreated group.
YENTREVE indeholder saccharose 
YENTREVE contains sucrose
Brug af YENTREVE sammen med mad, drikke og alkohol YENTREVE kan tages med og uden mad. 
YENTREVE with food, drink and alcohol
Medicin der øger niveauet af serotonin: Triptaner, tramadol, tryptophan, SSRI-præparater (såsom paroxetin og fluoxetin), SNRI-præparater (såsom venlafaxin), tricykliske antidepressiva (såsom clomipramin, amitriptylin), petidin, perikon og MAO-hæmmere (såsom moclobemid og linezolid). 
Medicines that increase the level of serotonin: Triptans, tramadol, tryptophan, SSRIs (such as paroxetine and fluoxetine), SNRIs (such as venlafaxine), tricyclic antidepressants (such as clomipramine, amitriptyline), pethidine, St John's Wort and MAOIs (such as moclobemide and linezolid).
20 mg kapslerne er blå og har påskriften "20 mg" og koden "9544". 
The 20 mg capsules are blue and are printed with '20 mg' and the code ‘9544'.
Kapselindhold: Hypromellose, hypromelloseacetatsuccinat, saccharose, saccharosekugler, talcum, titandioxid (E171), triethylcitrat (se sidst i pkt. 
Capsule content: hypromellose, hypromellose acetate succinate, sucrose, sugar spheres, talc, titanium dioxide (E171), triethyl citrate (See end of section 2 for further information on sucrose).
Edible black ink: Syntetisk sort jern oxid (E172), propylenglycol og shellac. 
Edible ink: synthetic black iron oxide (E172), propylene glycol, shellac.
Luftveje, thorax og mediastinum 
Respiratory, thoracic and mediastinal disorders Yawning
Det anbefales at udvise forsigtighed ved administration af duloxetin sammen med præparater, som hovedsageligt metaboliseres via CYP2D6 (risperidon, tricycliske antidepressiva [TCA'er] såsom nortriptylin, amitriptylin og imipramin), specielt hvis disse præparater har et snævert terapeutisk indeks (som f.eks. flecainid, propafenon og metoprolol). 
Caution is advised if YENTREVE is co-administered with medicinal products that are predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such as flecainide, propafenone and metoprolol).
Der foreligger endnu ikke data på langtidssikkerhed hos børn og unge hvad angår vækst, modning, kognitiv- og adfærdsudvikling ved brug af YENTREVE. 
Also, the long-term safety effects concerning growth, maturation, and cognitive and behavioural development of YENTREVE in this age group have not yet been demonstrated.
YENTREVE må ikke bruges til patienter med svært nedsat nyrefunktion (kreatininclearance <30 ml/min, se pkt. 
YENTREVE must not be used in patients with severe renal impairment (creatinine clearance <30 ml/min; see section 4.3).
Hvis det sker for Dem, bør De fortælle Deres læge dette. 
You should tell your doctor if this happens to you.
Symptomer på overdosering inkluderer søvnighed, koma, serotoninsyndrom (en sjælden bivirkning, som kan forårsage en unormal opstemthed, døsighed, klodsethed, rastløshed, en følelse af at være beruset, feber, svedtendens og muskelstivhed), krampeanfald, opkastning og hurtig puls. 
Symptoms of overdose include sleepiness, coma, serotonin syndrome (a rare reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles), fits, vomiting and fast heart rate.
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP (20 MG HÅRDE ENTEROKAPSLER) 
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS (20 mg hard gastroresistant capsules)
Dataanalysen af fire 12-ugers placebo-kontrollerede kliniske studier med patienter med SUI viste, at de rapporterede bivirkninger typisk indtrådte i den første uge af behandlingen. 
The data analysis of four 12-week, placebo-controlled clinical trials in patients with SUI, including 958 duloxetine-treated and 955 placebo-treated patients, showed that the onset of the reported adverse events typically occurred in the first week of therapy.
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP (40 MG HÅRDE ENTEROKAPSLER) 
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS (40 mg hard gastroresistant capsules)
• vægttab, vægtøgning 
• weight loss, weight gain
YENTREVE hårde enterokapsler indeholder saccharose. 
YENTREVE hard gastro-resistant capsules contain sucrose.
Meget sjælden blødning6 
Very Rare phosphokinase increased